A Relative Bioavailability Study of Metformin HCl 500 mg ER Tablets Under Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

January 31, 2004

Study Completion Date

January 31, 2004

Conditions
Healthy
Interventions
DRUG

Metformin HCl 500 mg tablets, single dose

A: Experimental Subjects received Alpharma formulated products under fasting conditions

DRUG

CLUCOPHAGE® XR 500 mg tablets, single dose

B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions

Trial Locations (1)

58102

PRACS Institute, Ltd., Fargo

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Actavis Inc.

INDUSTRY

NCT00865748 - A Relative Bioavailability Study of Metformin HCl 500 mg ER Tablets Under Fasting Conditions | Biotech Hunter | Biotech Hunter